Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | MMP9 | P14780 | 9/20 | 0.39 |
| ▸ | APLNR | P35414 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 10/20 | 0.37 |
| ▸ | MMP13 | P45452 | 10/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22590204 | 0.88 | SCN8A (0.41) | CNR2CNR1MMP9APLNRMMP1 | |
| SCHEMBL21773016 | 0.86 | CNR2 (0.42) | CNR2CNR1MMP9APLNRMMP1 | |
| SCHEMBL21772969 | 0.86 | CNR2 (0.42) | CNR2CNR1MMP9APLNRMMP1 | |
| SCHEMBL30845604 | 0.82 | CNR2 (0.42) | CNR2CNR1MMP9APLNRMMP1 | |
| SCHEMBL19631623 | 0.81 | MMP9 (0.36) | CNR2CNR1MMP9APLNRMMP1 | |
| SCHEMBL21773210 | 0.80 | SCN1A (0.39) | MMP9MMP1MMP13LMNAADAM17 | |
| SCHEMBL21773280 | 0.80 | MMP9 (0.36) | CNR2CNR1MMP9MMP1MMP13 | |
| SCHEMBL21773285 | 0.80 | MMP9 (0.36) | CNR2CNR1MMP9MMP1MMP13 | |
| SCHEMBL21773278 | 0.80 | MMP9 (0.36) | CNR2CNR1MMP9MMP1MMP13 | |
| SCHEMBL19631690 | 0.79 | SCN8A (0.35) | CNR2CNR1MMP9APLNRMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2020-08-25 | — | — | US | disclosed |
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | SCN1A, SCN2A, SCN2B | CNR2 371/4885CNR1 749/4885MMP9 2673/4885 |
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | SCN1A, SCN2A, SCN2B | CNR2 371/4885CNR1 749/4885MMP9 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.